Fig. 3
From: A feasibility of computational drug screening for Fuchs endothelial corneal dystrophy
Computational drug screening results from L1000CDS2 and SigCom LINCS platforms. (A) L1000CDS2 analysis results showing the top 14 drug candidates identified from screening of FECD-associated DEGs (706 upregulated and 962 downregulated genes from FECD patients with TCF4 TNR > 50). The table displays comprehensive information, including rank, search score, gene overlap visualization, perturbation details, and experimental conditions (cell line, dose, and duration of treatment). (B) Heat map visualization of gene expression signatures for the top 50 drug candidates identified by L1000CDS2. The map illustrates the impact of each compound on FECD-associated DEGs, with rows representing input genes and columns representing drug candidates. Color intensity indicates the degree of expression changes (red: upregulation; blue: downregulation). (C, D) SigCom LINCS analysis results presenting the top 10 compounds categorized as (C) reversers (compounds that normalize FECD gene expression patterns) and (D) mimickers (compounds that enhance FECD-associated expression patterns). These visualizations were generated by the authors using the L1000CDS2 ( https://maayanlab.cloud/L1000CDS2/ ) and SigCom LINCS ( https://maayanlab.cloud/sigcom-lincs/ ) web-based tools, which are freely available for academic research under open access principles. The visualizations shown are direct outputs from our analysis using these tools and are displayed under academic fair use principles and in accordance with the tools’ terms of use.
